−540 KRW
−32.57 B KRW
18.86 B KRW
31.96 M
About CELLIVERY THERAPEUTICS, INC.
Sector
Industry
CEO
Dae-Woong Cho
Website
Headquarters
Seoul
Founded
2014
ISIN
KR7268600004
FIGI
BBG00M147R68
Cellivery Therapeutics, Inc. engages in the research and development of medicine and pharmaceutical products. Its products include improved cell-permeable parkin (iCP-Parkin), cell/tissue permeable frataxin (CP-FXN), improved cell-permeable SOCS3 (iCP-SOCS3), cell-permeable BMP2 (CP-BMP2), cell-permeable truncated SOCS3 (CP-SD), improved cell-permeable nuclear import inhibitor (iCP-NI), and others. The company was founded by Dae-Woong Cho on March 14, 2014 and is headquartered in Seoul, South Korea.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 268600 is 6,680 KRW — it has decreased by −29.91% in the past 24 hours. Watch CELLIVERY THERAPEUTICS, INC. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on KRX exchange CELLIVERY THERAPEUTICS, INC. stocks are traded under the ticker 268600.
268600 reached its all-time high on Jan 26, 2021 with the price of 103,430 KRW, and its all-time low was 4,910 KRW and was reached on Dec 19, 2018. View more price dynamics on 268600 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
268600 stock is 42.66% volatile and has beta coefficient of 5.70. Track CELLIVERY THERAPEUTICS, INC. stock price on the chart and check out the list of the most volatile stocks — is CELLIVERY THERAPEUTICS, INC. there?
Yes, you can track CELLIVERY THERAPEUTICS, INC. financials in yearly and quarterly reports right on TradingView.
268600 net income for the last quarter is −1.31 B KRW, while the quarter before that showed −1.40 B KRW of net income which accounts for 6.28% change. Track more CELLIVERY THERAPEUTICS, INC. financial stats to get the full picture.
No, 268600 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 30, 2024, the company has 9.00 employees. See our rating of the largest employees — is CELLIVERY THERAPEUTICS, INC. on this list?
Like other stocks, 268600 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CELLIVERY THERAPEUTICS, INC. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CELLIVERY THERAPEUTICS, INC. technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CELLIVERY THERAPEUTICS, INC. stock shows the strong sell signal. See more of CELLIVERY THERAPEUTICS, INC. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.